Breast cancer is frequently oestrogen responsive and this has resulted in the widespread use of hormonal therapy in its treatment. The most commonly used endocrine agent is the anti-oestrogen, tamoxifen, which has traditionally been used to provide low toxicity palliation in women with advanced breast cancer (Manni, 1989) . More recently, it has been shown to be highly effective at reducing mortality when used as adjuvant therapy (Early Breast Cancer Trialists' Collaborative Group, 1992) and has been used as primary therapy for treating elderly women (Gazet et al., 1988 , Bates et al., 1992 .
Tamoxifen therapy is frequently of long duration and is not without side-effects. In addition, a significant proportion of women do not respond to endocrine therapy. There is therefore considerable interest in predicting accurately the likely benefit of tamoxifen therapy. Knowledge of the potential benefit to individual patients might avoid overtreatment and permit the most appropriate form of therapy to be used from the outset.
Several markers of oestrogen responsiveness in breast cancer have been described. The oestrogen receptor was the first, and approximately one-half of women with oestrogen receptor-positive primary tumours respond to tamoxifen on relapse (McGuire et al., 1975) . The oestrogen receptor mediates the effects of oestrogens on tumour cells and controls the expression of a number of genes by oestrogen, some of which may provide improved markers of oestrogen responsiveness. The progesterone receptor, which mediates the effects of progestins, and the pNR-2/pS2 protein, a 'trefoil' peptide of unknown function (Poulsom and Wright, 1993) , are both induced by oestrogens in oestrogen-responsive breast cancer cells in culture (Horwitz and McGuire, 1978; May and Westley, 1988) . Expression of both proteins is associated with responsiveness to endocrine therapy (Osborne et al., 1980; Henry et al., 1991) , although the relative merits of these markers remain unclear.
There are a number of clinical situations in which it would be beneficial to be able to predict oestrogen responsiveness using tumour cells obtained by fine-needle aspiration (FNA) at the time of diagnosis. For biochemical analysis. Among breast cancers diagnosed by screening, there is a significant proportion which do not provide sufficient material for conventional biochemical measurements. In addition, it is possible that in the future, small lesions will be destroyed in situ by techniques such as laser diathermy.
Among the techniques which allow the measurement of gene expression in small numbers of cells, reverse transcription-polymerase chain reaction (RT-PCR) potentially provides a rapid, sensitive method for measuring mRNA levels. The rate at which PCR products accumulate, however, depends on a variety of factors, including the sequence being amplified, the sequences of the PCR primers as well as the concentration of divalent cations, buffer composition and the type of reaction tube and thermocycler used. Because of the large number of variables, estimation of the amount of an mRNA put into a PCR reaction from either the amount of product at the end or the rate of accumulation of product during a PCR reaction is not trivial. A number of strategies have been described recently which attempt to overcome these problems (e.g. Hoof et al., 1991; Apostolakos et al., 1993; Clifford et al., 1994) and allow the quantitation of mRNA levels. In this report we describe the development of competitive RT-PCR assays based on the procedure described by Becker-Andre and Hahlbrock (1989) , for the measurement of oestrogen receptor, progesterone receptor and pNR-2/pS2 mRNA levels in RNA extracted from small numbers of breast cancer cells.
Materials and methods
Cell culture MCF-7, T47D, EFM-19 and MDA-MB-231 human breast cancer cells were cultured as described previously (May and Westley, 1986; Johnson et al., 1989) . In experiments in which RNA levels were measured in oestrogen-and tamoxifentreated cells, MCF-7 cells were first withdrawn from oestrogens present in routine culture medium and then stimulated with oestradiol and tamoxifen, also as described previously (May and Westley, 1988; Johnson et al., 1989 (May and Westley, 1986; Piggott et al., 1991) . It was transferred from pUC19 into KSM13-as a BamHI/EcoRI fragment.
BamHI sites were created within cloned cDNAs using in vitro mutagenesis as described by Kunkel et al. (1987) . Single-stranded DNA for in vitro mutagenesis was produced by single-stranded rescue in Escherichia coli CJ236. The mutagenic primers were 5'-GGTCTTTTC GGATCC GAC-CTT-3' for the oestrogen receptor, 5'-GAGGCC GGATCCA GAAGCCAG-3' for the progesterone receptor and 5'-GCGTCA GGATCC CAGGCAGATC-3' for pNR-2/pS2. The nucleotide being mutated is underlined.
Competitor RNA was synthesised from linearised, mutated plasmids using T7 DNA-dependent RNA polymerase. The mutated oestrogen receptor plasmid was linearised by KpnI, the mutated progesterone receptor plasmid by EcoRI and the mutated pNR-2 plasmid by HindIIl.
Competitive RT-PCR Primer pairs for PCR were selected by computer program (Diamond et al., 1990 Table I . cDNA corresponding to the three mRNAs measured in this study was inserted into the plasmid KSM 13-to allow the production of single-stranded DNA for in vitro mutagenesis by plasmid rescue and the synthesis of competitor RNA in vitro by transcription from the T7 promoter which is adjacent to the multiple cloning site. The cDNA inserts, together with the PCR target sequences and the positions of the engineered restriction enzyme site are shown diagrammatically in Figure 1 . The target sequence selected for the oestrogen receptor was located towards the C-terminus of the DNA-binding domain and traversed the third intron which is more than 32 kb long. For the progesterone receptor, the target sequence was located at the C-terminus of the B region and traversed the intron located pNR-2/pS2 cDNA at position 2380 in the mRNA sequence. The target sequence for pNR-2/pS2 contained the C-terminal half of the protein and most of the 3' non-coding region and traversed the second intron which is located at position 278 in the mRNA sequence.
BamHI sites were generated by site-directed mutagenesis as described in Materials and methods at the positions shown in c2+2cm+m2 = 1 where c is the proportion of PCR product derived from the cellular mRNA and m is the proportion of PCR product derived from the competitor mutated RNA. m2 represents the fraction of PCR product in the form of homoduplexes of molecules derived from the mutated RNA.
c2 represents the fraction of PCR product in the form of homoduplexes of molecules derived from cellular RNA. 2 cm is the fraction of PCR product in the form of heteroduplexes between molecules derived from the mutated and cellular RNA. As homoduplexes of molecules derived from the mutated RNA (m2) are cut by the restriction enzyme whereas homoduplexes derived from cellular RNA (c2) and heteroduplexes (2 cm) are not, the ratio of undigested-digested product is equivalent to c2 + 2 cm:m2.
When there are equal amounts of digested and undigested PCR products, m2 = 0.5 and therefore m = 0.71. As m + c = 1, then c = 0.29. Thus 71% of the PCR product is derived from mutated RNA while 29% is derived from the cellular RNA. Therefore, once the amount of synthetic RNA that must be added to the reverse transcription to produce equal amounts of digested and undigested PCR products is known, the amount of cellular mRNA present in the reverse transcription can be calculated by multiplying this amount by 29/71 = 0.41.
In practice, as can be seen in Figure 3 , the competitive RT-PCR reactions do not usually produce bands of equivalent intensity. The amount of mutated RNA required to give equal amounts of digested and undigested product is obtained by interpolation and various ways of plotting the data generated by this assay were therefore investigated. Theoretical curves were generated for the measurement by RT-PCR of 1 (V), 5 (U) and 25 (-) ng of non-mutated RNA in the presence of 0.1-100 ng of competitor mutated RNA. The equation, c2 + 2 cm + M2 = 1 was used to calculate the amount of digested and undigested PCR product for each hypothetical RT-PCR. The ratio of the amount of undigested and digested PCR products was plotted against the amount of competitor RNA added. When the data were plotted using linear or log-linear axes, the curves were nonlinear and the data highly compressed. Figure 4 shows the MDA-MB231 data plotted using logarithmic axes which produces nearlinear curves over the complete concentration range of competitor RNA. In addition, the curves corresponding to the different amounts of cellular RNA are parallel and allow the amount of added mutated RNA required to give bands of equal intensity to be easily determined.
The amount of the mRNA is then calculated by multiplying this figure by 0.41 as described above. In practice, a further correction is usually required because the cloned cDNA from which the competitor RNA is synthesised is usually shorter than the cellular mRNA. The correction fac- Figure 4 Theoretical curves of ratio of undigested and digested PCR product plotted against the amount of comnpetitor RNA. The proportion of digested and undigested PCR product were calculated when 0.1-100 ng of competitor mutant RNA was added to 1 (v), 5 (v) and 25 (@)ng of an RNA using the equation c2 + 2 cm +M2= 1 where m is the proportion of mutated RNA and c is the proportion of unmutated RNA in the RT-PCR. The axes are plotted on log scales. The horizontal dashed line represents equal amounts of digested and undigested PCR product (ratio = 1) and the vertical line shows that the amount of mutant added is 0.41 times the amount required to give equal amounts of digested and undigested PCR product.
7 cells. Figure 5 shows the log of the ratio of undigested-digested PCR product (log c2 + 2 cm/M2) plotted against the log of the amount of the competitor RNA (log m). Data are not plotted when only one PCR band is visible (resulting from a large excess of cellular or competitor RNA) as the ratio is meaningless (zero or infinity).
The amount of pNR-2/pS2 mRNA present in each sample of MCF-7 RNA was calculated as described in the previous section. This gave values of 0.09 pg pNR-2/pS2 RNA 4 ng-', 0.6 pg pNR-2/pS2 RNA 20 ng-' and 3.4 pg pNR-2/pS2 RNA 100 ng-' of MCF-7 RNA. These values are in close agreement and demonstrate that this RT-PCR assay is internally consistent over a 25-fold range of input RNA.
The concentrations of the oestrogen receptor, progesterone receptor and pNR-2/pS2 mRNAs were then measured in 100 ng total RNA extracted from three oestrogen-responsive (MCF-7, EFM-19 and T47D) and one non-responsive (MDA-MB-231) breast cancer cell lines. The amount of each mRNA in the four cell lines is shown in Table II same medium containing oestradiol and tamoxifen. The concentrations of pNR-2/pS2 mRNA were then measured in 100 ng of total RNA by the competitive RT-PCR assay as described above. Figure 6 shows the log of the ratio of undigested-digested PCR product (c2 + 2 cm/iM2) plotted against the log of the amount of competitor RNA added (m). pNR-2/pS2 mRNA was detectable at low levels, 2.96 pg 100 ng-' of total RNA in the withdrawn cells, at 6.8 pg 100 ng-' in the cells treated with tamoxifen and at 164 pg 100 ng -'in cells treated with oestradiol. Oestradiol therefore induced the pNR-2/pS2 mRNA 60-fold in this experiment. Tamoxifen had a small oestrogen agonist effect increasing pNR-2/pS2 mRNA concentrations 2.3-fold. This experiment shows that the competitive RT-PCR assay can be readily used to detect the induction of regulated mRNAs by steroids and gives qualitatively similar results to those obtained previously by hybridisation (May and Westley, 1987) .
Measurement of oestrogen receptor, progesterone receptor and pNR-2/pS2 mRNA in RNA extractedfrom fine needle aspirates The sensitivity of the competitive PCR assays suggested that they would allow quantitation of mRNA concentrations in tumour cells obtained by FNA. A small series of aspirates were taken from breast cancers, a proportion of the cells were examined histologically and RNA was extracted from the remainder as described in Materials and methods. The concentrations of the oestrogen receptor, progesterone receptor and pNR-2/pS2 mRNAs were measured by competitive PCR assay as described above. Figure 7 shows the results from two representative aspirates. All three mRNAs were detected in RNA extracted from (Figure 7) . The complete absence of these three mRNAs is typical of the pattern of expression found in cell lines such as MDA MB231 (Figure 3 and Table  I ) whose growth is completely oestrogen independent.
Discussion
The these markers could revive the use of primary tamoxifen, which has been criticised because of the unacceptably high frequency of local recurrence in unselected patients (Dixon, 1992 Despite the fact that previously used methods give imprecise quantitation, estimates of the abundance of the three mRNAs in this study are reasonably consistent with previously published data. For instance, the abundance of the pNR-2/pS2 mRNA was estimated to be 3.7 pg 100 ng-1 total RNA which is approximately 0.2% of mRNA assuming mRNA comprises 2% of total RNA. This is similar to our previous estimates based on the abundance of pNR-2 recombinants in a cDNA library (May and Westley, 1988 Immunohistochemistry is a powerful method for detecting protein expression in tumour cells and has become more widely used as the availability of antibodies has increased. Indeed antibodies are available against the oestrogen and progesterone receptor proteins and against the pNR-2/pS2 protein that react in sections from both formalin-fixed and frozen tissue. This technique is rarely constrained by the amount of tissue available, gives valuable information on the pattern of expression within tissues and has been described for cells obtained by FNA for both oestrogen receptor (Crawford et al., 1985; Flowers et al., 1985; Coombes et al., 1987; Gaskell et al., 1989; Davis et al., 1991) and pNR-2/pS2 (Wilson et al., 1994) . The major disadvantage of immunohistochemistry is its lack of quantitation and the requirement for antibodies that react well in tissue sections. Although a number of scoring methods have been used which take into account the number of positive cells as well as the intensity of staining, most studies use crude relatively subjective scoring systems. The lack of quantitative information does not allow retrospective analysis of data for optimal cut-off values and cannot identify tumours with high levels of expression that have the highest probability of responding to endocrine therapy. In contrast, competitive RT-PCR provides an attractive alternative to immunohistochemistry which can provide quantitative information and has the advantage that it does not require the development or purchase of specialist antibodies. The only constraint on setting up a competitive PCR assay is the availability of the sequence of the gene to be analysed. The competitive PCR assay may, in the future, be adaptable to RNA extracted from cells obtained by microdissection of tissue sections.
In conclusion, we have developed highly sensitive, quantitative, competitive RT-PCR assays for the measurement of the oestrogen receptor, progesterone receptor and pNR-2/ pS2 mRNAs. We suggest that these assays will be invaluable for predicting the potential benefit of endocrine therapy to individual patients and should enable rational decisions concerning therapy to be taken on material obtained at the time of diagnosis.
